↓ Skip to main content

Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia

Overview of attention for article published in Cancer Discovery, November 2023
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

news
10 news outlets
twitter
47 X users

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
32 Mendeley